DE69506561T2 - Immunkonjugate die tyrosine kinase inhibitoren enthalten - Google Patents

Immunkonjugate die tyrosine kinase inhibitoren enthalten

Info

Publication number
DE69506561T2
DE69506561T2 DE69506561T DE69506561T DE69506561T2 DE 69506561 T2 DE69506561 T2 DE 69506561T2 DE 69506561 T DE69506561 T DE 69506561T DE 69506561 T DE69506561 T DE 69506561T DE 69506561 T2 DE69506561 T2 DE 69506561T2
Authority
DE
Germany
Prior art keywords
tyrosine kinase
immuno
kinase inhibitors
conjugates contain
contain tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69506561T
Other languages
English (en)
Other versions
DE69506561D1 (de
Inventor
Fatih Uckun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Publication of DE69506561D1 publication Critical patent/DE69506561D1/de
Application granted granted Critical
Publication of DE69506561T2 publication Critical patent/DE69506561T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69506561T 1994-08-19 1995-08-08 Immunkonjugate die tyrosine kinase inhibitoren enthalten Expired - Fee Related DE69506561T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/293,731 US5587459A (en) 1994-08-19 1994-08-19 Immunoconjugates comprising tyrosine kinase inhibitors
PCT/US1995/010123 WO1996006116A1 (en) 1994-08-19 1995-08-08 Immunoconjugates comprising tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
DE69506561D1 DE69506561D1 (de) 1999-01-21
DE69506561T2 true DE69506561T2 (de) 1999-08-12

Family

ID=23130336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69506561T Expired - Fee Related DE69506561T2 (de) 1994-08-19 1995-08-08 Immunkonjugate die tyrosine kinase inhibitoren enthalten

Country Status (8)

Country Link
US (2) US5587459A (de)
EP (1) EP0776338B1 (de)
JP (1) JPH10505056A (de)
AT (1) ATE174345T1 (de)
AU (1) AU3216895A (de)
CA (1) CA2197577A1 (de)
DE (1) DE69506561T2 (de)
WO (1) WO1996006116A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
JPH11506915A (ja) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン
FR2742156A1 (fr) * 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
EP0946195A1 (de) * 1996-10-01 1999-10-06 Celltech Therapeutics Limited Pharmazeutisches produkt, welches tyrosin kinase inhibitoren und anti-cd4antikörpern enthält
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
JP2001518935A (ja) 1997-03-26 2001-10-16 バイオソース テクノロジーズ，インコーポレイティド 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体
AU7165798A (en) * 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
AU760046B2 (en) 1998-02-27 2003-05-08 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6051602A (en) * 1998-03-16 2000-04-18 The Procter & Gamble Company Methods for regulating skin appearance
WO1999050455A1 (en) * 1998-03-27 1999-10-07 Temple University - Of The Commonwealth System Of Higher Education Methods for cancer prognosis and screening antiproliferative agents
ATE350048T1 (de) * 1998-04-16 2007-01-15 Eurovita As Neue synergistische zusammensetzungen, die aromatische verbindungen und in alpinia galanga vorhandene terpenoide enthalten
WO1999055906A2 (en) * 1998-04-27 1999-11-04 University Health Network Gene screening methods and related assays
US6034053A (en) * 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1234585A3 (de) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Zusammensetzungen zur Vorbeugung oder Behandlung von Krebs
AU777970C (en) * 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
JP2003528805A (ja) * 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
CA2380888A1 (en) 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
DE10024069A1 (de) * 2000-05-17 2001-12-13 Gluesenkamp Karl Heinz Konjugat auf der Basis einer heterobifunktionalen Brückenverbindung, die mit einem Immunmodulator und einer zellerkennenden Einheit substituiert ist
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20040136908A1 (en) * 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
EP1519956B1 (de) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoklonale antikörper und deren anwendungsverfahren
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2269656B1 (de) 2002-07-15 2014-08-20 Board Of Regents, The University Of Texas Ausgewählte antikörper mit bindung an aminophospholipide und ihre verwendung bei der behandlung von krebs
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
JP2006523240A (ja) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド ＥｐｈＡ２、低増殖性細胞障害ならびに上皮および内皮の再構成
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
EP2316487B1 (de) 2003-04-11 2014-06-11 MedImmune, LLC Rekombinante IL-9 Antikörper und ihre Verwendung
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
KR20170102377A (ko) 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
EP2136831B1 (de) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogene peptide
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
DK2176298T3 (en) * 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
ES2437595T3 (es) 2007-12-20 2014-01-13 Novartis Ag Derivados de tiazol usados como inhibidores de la PI 3 quinasa
EP3470087A1 (de) 2009-02-13 2019-04-17 Immunomedics, Inc. Lyophilisierte zusammensetzungen von immunkonjugaten mit einem intrazellulär spaltbaren linker
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
EP2670426B1 (de) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodale trail-moleküle und ihre verwendungen in zelltherapien
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
MX340452B (es) 2011-10-28 2016-07-08 Novartis Ag Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
KR20150009540A (ko) 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP4063391A1 (de) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014035474A1 (en) * 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
KR20230078823A (ko) 2012-12-13 2023-06-02 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
PT3041507T (pt) 2013-08-26 2021-07-26 Biontech Res And Development Inc Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis
CN105979947A (zh) 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
HUE055189T2 (hu) 2014-06-04 2021-11-29 Biontech Res And Development Inc Humán monoklonális antitestek a GD2 ganglioziddal ellen
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016057398A1 (en) 2014-10-07 2016-04-14 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CA3026880A1 (en) 2016-06-08 2017-12-14 Paul Foster Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61246124A (ja) * 1985-04-24 1986-11-01 Yamanouchi Pharmaceut Co Ltd 制癌剤
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
US4831117A (en) * 1986-01-03 1989-05-16 Uckun Fatih M Monoclonal antibody specific for human B-cells
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
IN165717B (de) * 1986-08-07 1989-12-23 Battelle Memorial Institute
JPH03275625A (ja) * 1990-03-23 1991-12-06 Nippon Oil & Fats Co Ltd 制癌剤およびその製造法
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
AU3937693A (en) * 1992-04-10 1993-11-18 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents
USRE40792E1 (en) * 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
WO1994018345A1 (en) * 1993-02-05 1994-08-18 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
ES2150495T5 (es) * 1993-05-19 2007-02-16 Schering Corporation Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
EP0722489B1 (de) * 1993-09-08 2002-04-03 Imclone Systems, Inc. Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO1996006116A1 (en) 1996-02-29
JPH10505056A (ja) 1998-05-19
AU3216895A (en) 1996-03-14
EP0776338B1 (de) 1998-12-09
DE69506561D1 (de) 1999-01-21
US5872223A (en) 1999-02-16
ATE174345T1 (de) 1998-12-15
US5587459A (en) 1996-12-24
CA2197577A1 (en) 1996-02-29
EP0776338A1 (de) 1997-06-04

Similar Documents

Publication Publication Date Title
DE69506561D1 (de) Immunkonjugate die tyrosine kinase inhibitoren enthalten
HUP0003194A3 (en) Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
MXPA00011248A (es) Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
MY130363A (en) "pyrrole substituted 2-indolinone protein kinase inhibitors"
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
WO1993021942A3 (en) Use of mmp inhibitors
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
MX9706529A (es) Pirido (2,3-d)pirimidinas para inhibir la proliferacion celular mediada por la cinasa tirosina de proteinas.
AU7107496A (en) Protein tyrosine kinase inhibitors for treating osteoarthritis
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
ATE292121T1 (de) Chinazolinderivate
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
ATE296799T1 (de) P38-inhibitoren
BG103575A (en) SUBSTITUTED NITROGENCONTAINING HETEROCYCLES AS p38 PROTEINKINASE INHIBIRORS
NO984718L (no) Irreversible inhibitorer for tyrosin-kinaser
MX9800921A (es) Quinolonas y su uso terapeutico.
MX9800922A (es) Quinolonas y su uso terapeutico.
NO985652D0 (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
DK1272188T3 (da) Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer
CA2238283A1 (en) Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
ATE327973T1 (de) Polyamin-analoge als cytotoxische wirkstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee